Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
AssigneeSenju Pharmaceutical Co., Ltd.
InventorsTakeshi Nakajima, Emi Nakajima, Mitsuyoshi Azuma
Life of this patent
Estimating the term…
Abstract
Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1α expression and a substance specifically inhibiting HIF-2α expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1α and HIF-2α, or expression vectors thereof.
Claims17
A therapeutic agent for a retinal disease, comprising a substance specifically inhibiting HIF-1α expression and a substance specifically inhibiting HIF-2α expression.
-16. (canceled)
A method of treating a retinal disease, comprising a step of administering an effective amount of a substance specifically inhibiting expression of HIF-1α and an effective amount of a substance specifically inhibiting expression of HIF-2α to a subject in need of a treatment of retinal disease.
Dependencies are inferred from the claim text.